Profound LDL-C lowering with evolocumab significantly reduces ischemic risk in PAD | AHA

Evolocumab reduced LDL-C from a median of 93 mg/dl to 31 mg/dl
Evolocumab reduced LDL-C from a median of 93 mg/dl to 31 mg/dl